ArticleNature communications2024

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.

Victor Joo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.